close

Fundraisings and IPOs

Date: 2017-07-25

Type of information: Grant

Company: Iterum Therapeutics (Ireland)

Investors: Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA)

Amount: up to $ 1.5 million

Funding type: grant

Planned used:

  • The grant will support the development of  oral and intravenous formulations of sulopenem under investigation in Phase 1 clinical trials for the treatment of serious drug-resistant infections in hospital and community settings. These include the most urgent drug-resistant antimicrobial threats defined by the US Centers for Disease Control. Sulopenem is highly effective against the pathogens most commonly associated with uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections, including potent in-vitro activity against Enterobacteriaceae mutants of E. coli and K. pneumonia. If approved, sulopenem will be available as a tablet and an intravenous formulation. Future clinical studies will focus on urinary tract and complicated intra-abdominal infections. With careful stewardship from medical professionals and appropriate use by patients, sulopenem could be effective in the treatment of infections in patients in the community and could be useful in the early discharge of patients from hospital.  is headquartered in Dublin, Ireland. For more information: www.iterumtx.com. Media contact: Stephen Lederer at stephen.lederer@ymail.com
  • In February 2017, WHO  published its first ever list of antibiotic-resistant "priority pathogens" – a catalogue of 12 families of bacteria that pose the greatest threat to human health. The list was drawn up in a bid to guide and promote research and development (R&D) of new antibiotics, as part of WHO’s efforts to address growing global resistance to antimicrobial medicines. The list highlights in particular the threat of gram-negative bacteria that are resistant to multiple antibiotics. The WHO list is divided into three categories according to the urgency of need for new antibiotics: critical, high and medium priority.
  • – Priority 1: CRITICAL
  • Acinetobacter baumannii, carbapenem-resistant
  • Pseudomonas aeruginosa, carbapenem-resistant
  • Enterobacteriaceae, carbapenem-resistant, ESBL-producing
  • – Priority 2: HIGH
  • Enterococcus faecium, vancomycin-resistant
  • Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant
  • Helicobacter pylori, clarithromycin-resistant
  • Campylobacter spp., fluoroquinolone-resistant
  • Salmonellae, fluoroquinolone-resistant
  • Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant
  • – Priority 3: MEDIUM
  • Streptococcus pneumoniae, penicillin-non-susceptible
  • Haemophilus influenzae, ampicillin-resistant
  • Shigella spp., fluoroquinolone-resistant

Others:

  • • On July 25, 2017, Iterum Therapeutics has been awarded up to $  1.5 million non-dilutive funding from CARB-X, the world's largest public-private partnership devoted to antibacterial R&D.  was selected by CARB-X from a group of 368 applicants worldwide and is part of the first cohort that includes companies from Continental Europe.
  • CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is backed by the US Government – through the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) - and the UK charity Wellcome Trust. It was launched in July 2016 to address the gap in antibiotic research and development and innovations to improve diagnosis and treatment of drug-resistant infections. CARB-X will spend up to $455 million from 2017-2021 to support innovative products from 'hit-to-lead' stage through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. This charitable global public-private partnership is led by Boston University.

Therapeutic area: Infectious diseases

Is general: Yes